financetom
Business
financetom
/
Business
/
German car industry urges EU to drop tariffs on China-made cars
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
German car industry urges EU to drop tariffs on China-made cars
Jul 3, 2024 12:32 AM

BERLIN, July 3 (Reuters) - Germany's VDA auto

association urged the European Commission to drop its planned

tariffs on China-made electric vehicles on Wednesday, in a

last-ditch effort to influence negotiations ahead of the tariffs

kicking in on Thursday.

The association highlighted that the tariffs were hurting

European and U.S. carmakers exporting from China and that the

risk of retaliation by China with counter-tariffs would hit the

German industry hard given its high volume of export to China.

The value of passenger car exports from Germany to China

last year was over three times the value of imports from China,

and the value of exports by component suppliers was four times

as much as the value of imports, according to the VDA.

The Commission should instead focus on securing access to

critical raw materials - many of which are controlled by China -

for Europe's EV industry, reducing barriers to market access and

creating transparency on trade policy, the VDA said, proposing

the creation of a council to discuss such matters.

"Anti-subsidy tariffs are not an adequate measure to

strengthen European competitiveness and resilience in the long

term," it said.

China and the European Commission have been in negotiations

since last week over the curbs that Beijing wants scrapped,

rejecting accusations of unfair subsidies.

Brussels has made clear that it expected China to come to

technical talks taking place this week with a road map for

"addressing the injurious subsidisation" of its EV industry if

there were to be a negotiated outcome.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Catheter Precision Receives UK Approval for Suture Retention Device
Catheter Precision Receives UK Approval for Suture Retention Device
Aug 18, 2025
08:24 AM EDT, 08/18/2025 (MT Newswires) -- Catheter Precision ( VTAK ) said Monday that it has received registration and approval in the UK for its LockeT suture retention device, allowing it to launch sales in the nation. Catheter Precision ( VTAK ) said it has entered into an agreement with UK-based HC21 to distribute LockeT. LockeT received a CE...
Ultragenyx Pharmaceutical Begins Biologics License Application for Glycogen Storage Disease Gene Therapy
Ultragenyx Pharmaceutical Begins Biologics License Application for Glycogen Storage Disease Gene Therapy
Aug 18, 2025
08:23 AM EDT, 08/18/2025 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said Monday it initiated a rolling submission of a biologics license application for its DTX401 AAV gene therapy as treatment for glycogen storage disease Type Ia with the US Food and Drug Administration. The company said it aims to complete the full application, including submission of the chemistry,...
Opus Genetics Says FDA Approved Investigational New Drug Application for Retinal Diseases Drug Candidate
Opus Genetics Says FDA Approved Investigational New Drug Application for Retinal Diseases Drug Candidate
Aug 18, 2025
08:28 AM EDT, 08/18/2025 (MT Newswires) -- Opus Genetics ( IRD ) said Monday that the Investigational New Drug application for its OPGx-BEST1 gene therapy to treat bestrophin-1-related inherited retinal diseases was approved by the US Food and Drug Administration Following the approval, the company said it intends to start a phase 1/2 clinical trial in H2 2025 to evaluate...
Enlivex Therapeutics Says Allocetra Showed Improvements in Phase IIa Trial for Osteoarthritis
Enlivex Therapeutics Says Allocetra Showed Improvements in Phase IIa Trial for Osteoarthritis
Aug 18, 2025
08:25 AM EDT, 08/18/2025 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) shares were up over 11% premarket Monday after the company said its Allocetra cell therapy demonstrated improvements in a phase IIa trial in patients with moderate-to-severe knee osteoarthritis. The Allocetra treatment arm showed a 24% reduction in knee pain and a 26% improvement in knee function compared with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved